ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 38.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,920 shares of the biopharmaceutical company’s stock after selling 1,200 shares during the quarter. Nisa Investment Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $60,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of ACADIA Pharmaceuticals by 4.2% in the third quarter. Vanguard Group Inc. now owns 12,925,641 shares of the biopharmaceutical company’s stock worth $211,463,000 after acquiring an additional 525,048 shares during the period. RTW Investments LP increased its stake in shares of ACADIA Pharmaceuticals by 18.3% in the third quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock worth $241,255,000 after acquiring an additional 1,793,288 shares during the period. BlackRock Inc. increased its stake in shares of ACADIA Pharmaceuticals by 1.7% in the second quarter. BlackRock Inc. now owns 10,039,501 shares of the biopharmaceutical company’s stock worth $240,446,000 after acquiring an additional 170,370 shares during the period. State Street Corp increased its stake in shares of ACADIA Pharmaceuticals by 2.8% in the third quarter. State Street Corp now owns 6,778,871 shares of the biopharmaceutical company’s stock worth $110,902,000 after acquiring an additional 184,921 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of ACADIA Pharmaceuticals by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,550,906 shares of the biopharmaceutical company’s stock worth $85,649,000 after acquiring an additional 271,652 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Insider Transactions at ACADIA Pharmaceuticals

In other news, CEO Stephen Davis sold 26,574 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $474,877.38. Following the transaction, the chief executive officer now directly owns 144,267 shares of the company’s stock, valued at $2,578,051.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Stephen Davis sold 26,574 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $474,877.38. Following the transaction, the chief executive officer now directly owns 144,267 shares of the company’s stock, valued at $2,578,051.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James Kihara sold 1,790 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $17.87, for a total transaction of $31,987.30. Following the completion of the transaction, the insider now directly owns 13,100 shares in the company, valued at $234,097. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,383 shares of company stock valued at $1,291,362. Corporate insiders own 27.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Oppenheimer reiterated a “market perform” rating and issued a $25.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, February 5th. HC Wainwright reissued a “buy” rating and set a $33.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 28th. Mizuho downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $39.00 to $25.00 in a report on Tuesday, March 12th. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. Finally, TheStreet raised shares of ACADIA Pharmaceuticals from a “d” rating to a “c” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.82.

ACADIA Pharmaceuticals Stock Down 1.5 %

ACAD opened at $16.82 on Monday. The firm’s fifty day simple moving average is $20.84 and its two-hundred day simple moving average is $23.75. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -44.26 and a beta of 0.37. ACADIA Pharmaceuticals Inc. has a 52-week low of $16.60 and a 52-week high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). The business had revenue of $231.04 million during the quarter, compared to analysts’ expectations of $223.79 million. ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The business’s quarterly revenue was up 69.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share. On average, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.